- IBD
-
Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study
-
Xinyu Liu, Qingfan Yang, Na Diao, Jian Tang, Zicheng Huang, Xiang Gao, Kang Chao
-
Intest Res 2024;22(3):357-368. Published online May 7, 2024
-
DOI: https://doi.org/10.5217/ir.2023.00106
-
-
Abstract
PDF Supplementary Material PubReader ePub
- Background/Aims
Data on the natural course of Chinese patients with ulcerative colitis (UC) was lacking. This study aimed to evaluate the natural history and prognosis of patients with UC in the past 15 years in China.
Methods This cohort study included patients with UC in a tertiary hospital in southern China from 2007 to 2021 (cohort I: 2007–2011, cohort II: 2012–2016, cohort III: 2017–2021). Patients’ clinical characteristics and natural history were analyzed retrospectively.
Results Of 1,139 included patients, 683 patients presented with proctitis or left-sided colitis at diagnosis and 38.5% of them (263/683) developed proximal disease extension. Fifty-eight percent of patients experienced relapse, chronic continuous and intermittent active course. Five patients (0.4%) developed colorectal tumors/dysplasia. The overall surgery rate was 8.6%, and the rates were 14.2%, 7.8%, and 8.0% in the 3 cohorts, respectively (P= 0.059). Average time from diagnosis to surgery decreased from cohorts I to III (144 months vs. 36 months, P< 0.001), so did the use of glucocorticoids (58.2% vs. 43.5%, P< 0.001) and immunosuppressants (14.1% vs. 13.4%, P= 0.016), and days of hospitalization (13 days vs. 9 days, P< 0.001). Biologics were used more frequently during the first year (0.8%, 2.1%, and 13.7% for cohorts I to III, respectively; P< 0.001). The rate of mucosal healing increased over time.
Conclusions In Chinese UC patients, one-third of patients experienced proximal disease extension. The rates of malignancy and mortality were low. More biologics were used, while use of immunosuppressants and glucocorticoids were reduced over time. Early biologics use seemed to promote mucosal healing, but the rate of colectomy has not dramatically decreased.
-
Citations
Citations to this article as recorded by 
- Manejo de la proctitis ulcerosa refractaria
Manuel Barreiro-de Acosta, Francisco Mesonero, Rocío Ferreiro-Iglesias, Santiago García-López, Mariam Aguas Peris, Mónica Sierra Ausín, Noelia Cano Sanz, Antonio Valdivia Martínez, Ana Cábez, Susan Ramírez, Daniel Ginard Gastroenterología y Hepatología.2026; 49(5): 502646. CrossRef - Leveraging patient-reported outcomes and serum markers to predict active ulcerative colitis: a multicenter cohort
Wenqian Li, Xin Hao, Yunyun Sun, Caimin Li, Mei Wang, Sicong Hou Frontiers in Medicine.2026;[Epub] CrossRef - Management of refractory ulcerative proctitis
Manuel Barreiro-de Acosta, Francisco Mesonero, Rocío Ferreiro-Iglesias, Santiago García-López, Mariam Aguas Peris, Mónica Sierra Ausín, Noelia Cano Sanz, Antonio Valdivia Martínez, Ana Cábez, Susan Ramírez, Daniel Ginard Gastroenterología y Hepatología (English Edition).2026; 49(5): 502646. CrossRef - Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations
Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, Yoo Jin Lee, Eun Mi Song, Dae Sung Kim, Chun-Chi Lin, Joyce Wing Yan Mak, Jing Liu, Qian Cao, Shu-Chen Wei, We Inflammatory Bowel Diseases.2026; 32(10): 1957. CrossRef - Targeting mitochondrial dysfunction with traditional Chinese medicine for inflammatory bowel disease: a comprehensive review
Linxi Zeng, Yao Huang, Jiayi Ke, Jiaqi Han, Wenda Xie, Zhishan Ding, Fangmei Zhou Frontiers in Pharmacology.2026;[Epub] CrossRef - ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
Michel Adamina, Peter Kienle, María Chaparro, Bram Verstockt, Silvia Minozzi, Mariangela Allocca, Raja Atreya, Nicolas Avellaneda, Manuel Barreiro-De Acosta, Robert Battat, Dominik Bettenworth, Irina Blumenstein, Steven R Brown, John P Burke, Flavio Capri Journal of Crohn's and Colitis.2026;[Epub] CrossRef - Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort
Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee Journal of Gastroenterology and Hepatology.2026; 41(8): 2338. CrossRef - The effects of biologics on ulcerative colitis–related colectomy rate: results of a 22-year study
Nur Beyza Tukek, Oguz Kagan Bakkaloglu, Gozde Sen, İbrahim Hatemi, Aykut Ferhat Celik, Yusuf Ziya Erzin Scandinavian Journal of Gastroenterology.2025; 60(6): 548. CrossRef - Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan
Qi Sun, Zhixian Jiang, Lichao Yang, Hao Liu, Peipei Song, Lianwen Yuan Intractable & Rare Diseases Research.2025; 14(3): 192. CrossRef - Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU
Francisco Mesonero, López-García Alicia, Miranda-Bautista José, Rubín de Célix Cristina, Marín-Jiménez Ignacio, Suárez Ferrer Cristina, Martin-Cardona Albert, Fuentes-Valenzuela Esteban, Mínguez Alejando, Castaño Andrés, Roig Cristina, Fernández-Clotet Ag Journal of Crohn’s and Colitis.2025;[Epub] CrossRef
-
11,770
View
-
237
Download
-
9
Web of Science
-
10
Crossref
|